Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson’s disease

Close metadata

OBJECTIVE

To study, using a complex morphochemical approach, the localization of alpha-synuclein, iron compounds and iron-containing proteins in the structures of the substantia nigra of the brain in Parkinson’s disease (PD).

MATERIAL AND METHODS

Histochemistry and immunohistochemistry methods have been used to study the localization of pathological alpha-synuclein (α-Syn-p129), iron compounds and iron-containing proteins — transferrin receptor and ferritin in neurons and neuroglia in the substantia nigra of the brain of deceased PD patients and persons with no neurological symptoms detected during life (control).

RESULTS

In the substantia nigra of PD patients, in comparison with the control, a stable accumulation of pathological alpha-synuclein (α-Syn-p129) in the bodies and processes of neurons was found, and in the neuroglia and neuropil — the accumulation of iron (II) and ferritin heavy chain, the reaction of microglia to protein CD68 was moderately elevated. The transmembrane protein CD71 was detected equally in the brains of PD patients and in controls.

CONCLUSION

Synaptic protein alpha-synuclein in PD turns into a pathological metabolite that accumulates in the structures of substantia nigra, and probably disrupts the conduction of nervous excitation. Excessive accumulation of the ferritin heavy chain in neuroglia can increase the concentration of reactive forms of iron and increase neurotoxicity. The uniform distribution of the transmembrane glycoprotein CD71 in the of substantia nigra structures both in the control and in PD patients indicates the preservation of non-heme iron transport during the neurodegenerative process.

Keywords:

human brain

substantia nigra

Parkinson’s disease

alpha-synuclein

iron

transferrin receptor

ferritin

Authors:

Salkov V.N.

Scientific Center of Neurology

Khudoyerkov R.M.

Scientific Center of Neurology

Voronkov D.N.

Research Center of Neurology

Sobolev V.B.

Research Center of Neurology

Received:

10.11.2021

Accepted:

22.12.2021

List of references:

Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901-905. https://doi.org/10.1007/s00702-017-1686-y
Trist BG, Hare DJ, Double KL. A proposed mechanism for neurodegeneration in movement disorders characterized by metal dyshomeostasis and oxidative stress. Cell Chem Biol. 2018;25(7):807-816. https://doi.org/10.1016/j.chembiol.2018.05.004
Dusek P, Roos PM, Litwin T, Schneider SA, Flaten TP, Aaseth J. The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases. J Trace Elem Med Biol. 2015;31:193-203. https://doi.org/10/1016/j.jtemb.2014.05.007
Gallegos S, Pacheco C, Peters C, Opazo CM, Aguayo LG. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease. Front Neurosci. 2015;(9):59. https://doi.org/10.3389/fnins.2015.00059
Walker DG, Lue LF, Adler CH, Shill H, Caviness J, Sabbagh M, Akiyama H, Serrano G, Sue L, Beach T. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2013;240:190-204. https://doi.org/10.1016/j.expneurol.2012.11.020
Jellinger KA. Lewy body-related α-synucleinopathy in the aged human brain. J Neural Transm (Vienna). 2004;111(10-11):1219-1235. https://doi.org/10.1007/s00702-004-0138-7
Jellinger KA. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Mov Disord. 2011;27(1):8-30. https://doi.org/10.1002/mds.23795
Cersosimo MG, Perandones C, Micheli FE, Raina GB, Beron AM, Nasswetter G, Radrizzani M, Benarroch EE. Alpha-synuclein immunoreactivity in minor salivary gland biopsies in Parkinson’s disease patients. Mov Disord. 2011;26(1):188-190. https://doi.org/10.1002/mds.23344
Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2(8). Accessed October 12, 2021. https://doi.org/10.1101/cshperspect.a009258
Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA. 2004;101(26):9843-9848. https://doi.org/10.1073/pnas.0403495101
Carboni E, Lingor P. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease. Metallomics. 2015;7:395-404. https://doi.org/10.1039/c4mt00339j
Reinert A, Morawski M, Seeger J, Arendt T, Reinert T. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci. 2019;20(1):25. Accessed October 12, 2021. https://doi.org/10.1186/s12868-019-0507-7
Morawski M, Meinecke C, Reinert T, Dorffel AC, Riederer P, Arendt T, Butz T. Determination of trace elements in the human substantia nigra. Nucl Instrum Methods Phys Res Sect B. 2005;231:224-228. https://doi.org/10.1016/j.nimb.2005.01.061
Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB. Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm Park Dis Dement Sect. 1990;2(4):327-340. https://doi.org/10.1007/BF02252926
Faucheux BA, Martin ME, Beaumont C, Hunot S, Hauw JJ, Agid Y, Hirsch EC. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson’s disease. J Neurochem. 2002;83(2):320-330. https://doi.org/10.1046/j.1471-4159.2002.01118.x
Korzhevskii DE, Sukhorukova EG, Grigor’ev IP. The distribution of iron in the substantia nigra in the human brain. S.S. Korsakov Journal of Neurology and Psychiatry=Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(6):77-80. (In Russ.). Accessed October 12, 2021. https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2013/6/031997-72982013614
Genoud S, Roberts BR, Gunn AP, Halliday GM, Lewis SJG, Ball HJ, Hare DJ, Double KL. Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson’s disease brain. Metallomics. 2017;9(10):1447-1455. https://doi.org/10.1039/c7mt00244k
Li K, Reichman H. Role of iron in neurodegenerative diseases. J Neural Transm. 2016;123(4):389-399. https://doi.org/10.1007/s00702-016-1508-7
Madhavi T. Inflammation in Parkinson’s disease: scientific and clinical aspects. Springer; 2014. Accessed October 12, 2021. https://doi.org/10.1007/978-3-319-08046-8
Pchelina SN. Alpha-synuclein as a biomarker of Parkinson’s disease. Annals of Clinical and Experimental Neurology=Annaly Klinicheskoy I Experimental’noy Nevrologii. 2011;5(4):46-51. (In Russ.). Accessed October 12, 2021. https://annaly-nevrologii.com/wp-content/uploads/2016/09/Stranitsy-iz-Tom-5-4-2011-9.pdf
Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136(8):2419-2431. https://doi.org/10.1093/brain/awt192
Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res. 2003;5:35-44. https://doi.org/10.1007/bf03033371
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045-1060. https://doi.org/10.1016/s1474-4422(14)70117-6
Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem. 2003;86(5):1142-1148. https://doi.org/10.1046/j.1471-4159.2003.01923.x

Close metadata